Quest Pharmatech Inc V.QPT

Alternate Symbol(s): QPTFF

Healthcare Biotechnology

Quest PharmaTech Inc. is a Canadian biopharmaceutical company. The Company is developing products to improve the quality of life. It is developing the proprietary, MAb-AR9.6, targeting MUC16 as a diagnostic agent for cancer. MAb-AR9.6 is licensed from the University of Nebraska Medical Centre and is in late preclinical stage development. The Company has a 42.5% ownership interest in OncoQuest Inc., which is a biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest Inc.’s technology platform includes a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer in the Greater China territory.

TSXV:QPT - Post by User

Quest Pharmatech Inc

Bullboard Posts

Comment by lscfaon Apr 28, 2020 2:25pm

135 Views

Post# 30962988

RE:contracts filed on sedar

Does nothing for short-term cash flow to Quest.

Oncoquest gets Dual bonds which pay 0% interest and are not convetible into Dual common stock for 1 year after closing date (~June 30, 2020)

Oncoquest gets Dual stock at 2nd closing which is ~ December 31, 2020.

"The consideration received by OncoQuest from the transaction, net of transaction fees and expenses and income taxes, will be distributed to OncoQuest's shareholders, including Quest."

Bullboard Posts

Bitcoin company adds convenience of modern banking